ADMS = MC $107 M-- Cash $160 M--MS Walking P3 Data imminent Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADMS = MC $107 M-- Cash $160 M--MS Walking P3 Data imminent

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: BioHero	10/15/2019 3:30:49 PM
	Read Replies (1) of 3

"The company is also poised to begin receiving royalty payments in the low to mid-teens millions on sales of dementia drug Namzaric beginning in May 2020. Allergan reported total sales of $93 million for the drug through the first nine months of 2018. In other words, the future looks promising for the punching bag named Adamas Pharmaceuticals."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext